“Using AI to design a fleet of AAV delivery vehicles to create the FedEx for gene therapy.”
Gene therapy, with its potential to alter genes inside a patient’s cells, could be one of our most powerful tools in medicine—it holds the promise of “one-and-done” cures for genetic diseases. When it comes to these diseases, we often know precisely the genetic payloads we want to deliver, but don’t always have the right vehicles to deliver them into the relevant cells in the body. Adeno-associated virus (AAV), considered to be largely harmless to humans, is the primary workhorse vehicle (vector) we use today to deliver therapeutic genes in the body. But AAV has its limitations: it may not deliver enough of its genetic payload to the right cells, it’s difficult to manufacture, it can have serious safety issues at very high doses, and many patients are not candidates for AAV-based therapies because they have pre-existing immunity to certain AAVs. We currently have just two approved gene therapies, but the industry hopes to have as many as 10-20 cell and gene therapy approvals per year by the end of 2025. Gene therapy has the potential to treat—and even cure—thousands of devastating diseases. Can AAVs deliver?
AAVs’ therapeutic potential was originally observed over 20 years ago. Since then, scientists have pursued multiple approaches to discover, evolve, or design novel AAVs with enhanced properties and characteristics. Can we find an AAV that specifically targets, say, the central nervous system in order to treat neurodegenerative diseases? Or design an AAV that’s easier to manufacture? It’s a hard mountain to climb. AAV capsids (shells) are delicate, complex 20-sided structures. When it comes to manipulating them in order to improve them, one false step can result in a precipitous “fall” that breaks the capsid. And even if you can make progress on optimizing one property (like tissue-specific targeting), it often comes at the significant expense of others (like manufacturability and immunogenicity). Which is why traditional approaches—directed evolution or rational design, or even the hope of discovering other naturally occurring AAVs—have rarely yielded improved capsids. A more powerful approach is needed to escape the limitations of natural AAVs and fully realize the promise of gene therapy.
Dyno’s Ascent
In rock climbing, a “dyno” is a rapid move across a rock face in order to reach the next hold. Eric Kelsic, who studied physics at Caltech and trained at George Church’s famed Harvard lab, was thinking about the toughest, most valuable problems artificial intelligence (AI) could tackle in biology—and realized that AI was an ideal tool to accelerate the search for better AAVs. In 2018, he teamed up with machine learning expert (and fellow Church Lab alum) Sam Sinai, Adrian Veres, Tomas Bjorklund, seasoned biotech entrepreneur Alan Crane, and George Church to found Dyno Therapeutics. Dyno’s mission is to create AI-designed AAV vectors with transformative delivery properties to cover the vast landscape of human diseases. The company’s CapsidMap platform comprehensively surveys AAV topography and finds the best routes to optimize multiple parameters in parallel in order to rapidly generate more efficient, highly specific, and less immunogenic AAVs. In comparison to traditional methods, Dyno’s AI-driven approach has already proven to be highly prolific: they have designed enhanced liver-targeting variants of naturally occurring AAV capsids and screened billions of potential sequences in silico using machine learning models to design thousands of viable synthetic AAV capsids—validating the use of advanced machine learning models to design highly diverse, functional AAV capsids.
In addition to creating transformative therapies, productive bio platforms can enable novel business models too. If AI is an ideal tool for designing a diverse array of novel AAVs with varied functions, AI-designed AAVs can accelerate and reshape the entire gene therapy industry. From its inception, Dyno chose to eschew the traditional approach of investing in its own product pipeline (i.e. developing its own gene therapies) and instead decided to build the platform that will serve as the horizontal “infrastructure” layer to supply novel AAVs to power all gene therapies. Dyno’s approach has already proven to be highly prolific here too: the company has signed partnerships, potentially worth over $4 billion in aggregate, to develop next-generation AAV vectors for gene therapy leaders like Sarepta in muscle diseases, Novartis in eye diseases, and Roche/Spark Therapeutics for the central nervous system and liver. And this is just the start of their climb.
I am thrilled to announce that a16z is leading the Series A investment in Dyno. This capital will help expand their team and dramatically accelerate the design and development of improved AAV vectors targeting areas currently inaccessible to gene therapies—like lung, heart, and kidney diseases. I am honored to join the Board of Directors and to partner with CEO Eric Kelsic and team as Dyno delivers on its vision to scale new heights in gene therapy.
* * *
The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, this content may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein.
This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments for which the issuer has not provided permission for a16z to disclose publicly as well as unannounced investments in publicly traded digital assets) is available at https://a16z.com/investments/.
Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see https://a16z.com/disclosures for additional important information.